REFERENCES
- The DAD Writing Committee. Cardio- and cerebrovascu-lar events in HIV-infected persons. AIDS. 2004;18:1811–1817.
- Hsue PY, Lo JC, Franklin A, et al. Progression of athero-sclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109(13): 1603–1608.
- The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. New Engl J Med. 2007; 356(17):1723–1735.
- Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51—F58.
- Hruz PW, Murata H, Mueckler M. Adverse metabolic con-sequences of HIV protease inhibitor therapy: the search for a central mechanism. Am J Physiol Endocrinol Metab. 2001;280(4):E549—E553.
- Shishehbor MH, Hazen SL. Inflammatory and oxidative markers in atherosclerosis: relationship to outcome. Curr Atheroscler Rep. 2004;6(3):243–250.
- Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001286: 2136–2142.
- Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595–1604.
- Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440–1445.
- Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxi-dase levels independently predict endothelial dysfunction in humans. Circulation. 2004;110(9):1134–1139.
- Phillips A, Carr A, Neuhaus J, Visnegarwala F, Prineas R, Burman W, et al. Interruption of ART and risk of cardio-vascular disease: findings from SMART. In: Program and abstracts from the 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles. Ab-stract 41.
- Torriani FJ, Komarow L, Cotter BR, Murphy RL, Fichten-baum CJ, Currier JS, et al. Control of HIV viral replication is associated with rapid improvement in endothelial function sustained over 24 weeks: A5152s, a substudy of A5142. Antiviral Ther 2007;12(Suppl 2): L15.
- Ross A, Armentrout R, O'Riordan M, Storer N, Rizk N, Harrill D, et al. Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy (ART) and lipoatrophy. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 2008; Boston, MA.